Pages that link to "Item:Q2861956"
From MaRDI portal
The following pages link to Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes (Q2861956):
Displaying 11 items.
- A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes (Q2057378) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- A Bayesian Phase I/II Trial Design for Immunotherapy (Q4559685) (← links)
- Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics (Q6079344) (← links)
- Evaluating the use of generalized dynamic weighted ordinary least squares for individualized HIV treatment strategies (Q6179138) (← links)
- A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications (Q6622241) (← links)
- A phase I--II design based on periodic and continuous monitoring of disease status and the times to toxicity and death (Q6627403) (← links)
- A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials (Q6627894) (← links)
- Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens (Q6628011) (← links)
- Group sequential designs for clinical trials with bivariate endpoints (Q6629838) (← links)
- A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules (Q6629855) (← links)
